DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase

68Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Background - The clinical benefit of the administration of aerosolised recombinant human DNase (rhDNase) on pulmonary function in patients with cystic fibrosis has already been demonstrated but the biochemical action of rhDNase on DNA in bronchial secretions in vivo has not yet been investigated. Methods - Sputum was collected from 135 patients with cystic fibrosis before and during treatment with aerosolised rhDNase and examined to ascertain DNA concentration and length by colorimetric assay and densitometry of gel separated DNA. Results - Treatment with rhDNase reduced the concentration and the size of extracellular DNA in the sputum. The median interquartile range ofDNA length decreased from 0 5-2 6 kbp before treatment to 0-3-1P0 kbp during treatment. Conclusions - rhDNase was delivered to the secretions and was enzymatically active in vivo.

Author supplied keywords

Cite

CITATION STYLE

APA

Brandt, T., Breitenstein, S., Von Der Hardt, H., & Tümmler, B. (1995). DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax, 50(8), 880–882. https://doi.org/10.1136/thx.50.8.880

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free